or Try an Advanced Search...

    Technical Analysis for CANF - Can-Fite Biopharma Ltd Sponsored ADR (Israel)

    Grade Last Price % Change Price Change
    F 2.05 -3.76% -0.08
    CANF closed down 3.76 percent on Wednesday, May 15, 2024, on 35 percent of normal volume. It ran into resistance at its 50 day moving average.
    Earnings due: May 30
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical CANF trend table...
    Date Alert Name Type % Chg
    50 DMA Resistance Bearish 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Outside Day Range Expansion 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    50 DMA Resistance Bearish -3.76%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.76%
    Upper Bollinger Band Touch Strength -3.76%
    Gapped Down Weakness -3.76%
    50 DMA Resistance Bearish -3.98%
    Narrow Range Bar Range Contraction -3.98%
    Older End-of-Day Signals for CANF ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 10 hours ago
    50 DMA Resistance about 10 hours ago
    Outside Day about 10 hours ago
    Down 3% about 10 hours ago
    Non-ADX 1,2,3,4 Bearish Retracement Entry about 10 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    CANF Chart by TradingView
    Basic chart:

    Profile

    Can-Fite BioPharma, Ltd., a biotechnology company, develops drugs for the treatment of cancer and autoimmune inflammatory diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis; and has completed Phase II study for the treatment of rheumatoid arthritis and glaucoma, as well as completed Phase III study for the treatment of dry eye and Phase I study for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of hepatocellular carcinoma; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company was founded in 2000 and is based in Petach Tikva, Israel.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Immunology Treatment Of Cancer Inflammatory Diseases Rheumatoid Arthritis Psoriasis Carcinoma Glaucoma Arthritis Hepatocellular Carcinoma Uveitis Immunosuppressants Biotie Therapies Treatment Of Inflammatory Disease Treatment Of Inflammatory Diseases Treatment Of Psoriasis

    Is CANF a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 13 Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study
    May 10 Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    May 10 Can-Fite receives FDA IND clearance for Phase IIb MASH treatment trial
    May 9 Can-Fite stock up on FDA IND clearance for namodenoson to treat MASH patients in mid-stage study
    May 9 Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
    May 6 Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
    Apr 29 Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
    Apr 25 Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
    Apr 15 Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
    Apr 3 Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
    See more CANF news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.33
    52 Week Low 1.81
    Average Volume 18,862
    200-Day Moving Average 2.25
    50-Day Moving Average 2.14
    20-Day Moving Average 2.04
    10-Day Moving Average 2.09
    Average True Range 0.14
    RSI (14) 47.09
    ADX 28.53
    +DI 26.43
    -DI 9.94
    Chandelier Exit (Long, 3 ATRs) 1.90
    Chandelier Exit (Short, 3 ATRs) 2.33
    Upper Bollinger Bands 2.17
    Lower Bollinger Band 1.90
    Percent B (%b) 0.55
    BandWidth 13.32
    MACD Line -0.01
    MACD Signal Line -0.02
    MACD Histogram 0.012
    Fundamentals Value
    Market Cap 12.4 Million
    Num Shares 6.05 Million
    EPS -1.48
    Price-to-Earnings (P/E) Ratio -1.39
    Price-to-Sales 17.07
    Price-to-Book 2.38
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.32
    Resistance 3 (R3) 2.35 2.29 2.28
    Resistance 2 (R2) 2.29 2.22 2.28 2.26
    Resistance 1 (R1) 2.17 2.18 2.14 2.14 2.24
    Pivot Point 2.11 2.11 2.10 2.10 2.11
    Support 1 (S1) 1.99 2.04 1.96 1.96 1.86
    Support 2 (S2) 1.93 2.00 1.92 1.84
    Support 3 (S3) 1.81 1.93 1.83
    Support 4 (S4) 1.78